0 results found with selected filters. Please refine the filters. Redirecting to initial search..
Table "column sort" updates the order of the bars in the chart.
downloaded on: 2025/02/15 21:41:52
Strain |
Phenotype |
Conditions |
Study |
Experiment Name |
Sex |
Age |
# of Animals |
Value |
Units |
SEM |
SD |
Method |
Method Duration |
Post Insult Time Value |
Clinical Measurement Notes |
Record ID |
Study ID |
LOU/M |
maximum tumor size decrease to pretreatment tumor size ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (1 mg/kg) (for 21 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
90.8 |
% |
|
12.7 |
in vivo caliper method |
0.0 |
0 |
Experiment 1 |
109482 |
3146 |
LOU/M |
maximum tumor size decrease to pretreatment tumor size ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (0.5 mg/kg) (for 21 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
63.6 |
% |
|
31.2 |
in vivo caliper method |
0.0 |
0 |
Experiment 2 |
109491 |
3146 |
LOU/M |
maximum tumor size decrease to pretreatment tumor size ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (2 mg/kg) (for 21 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
78.5 |
% |
|
16.7 |
in vivo caliper method |
0.0 |
0 |
Experiment 1 |
109483 |
3146 |
LOU/M |
maximum tumor size decrease to pretreatment tumor size ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then cisplatin (0.5 mg/kg) (for 21 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
66.7 |
% |
|
25.4 |
in vivo caliper method |
0.0 |
0 |
Experiment 2 |
109488 |
3146 |
LOU/M |
maximum tumor size decrease to pretreatment tumor size ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (0.25 mg/kg) (for 21 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
-2.5 |
% |
|
15.9 |
in vivo caliper method |
0.0 |
0 |
Experiment 2 |
109490 |
3146 |
LOU/M |
maximum tumor size decrease to pretreatment tumor size ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then cisplatin (1 mg/kg) (for 21 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
100.0 |
% |
|
0.0 |
in vivo caliper method |
0.0 |
0 |
Experiment 1 |
109481 |
3146 |
LOU/M |
maximum tumor size decrease to pretreatment tumor size ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then cisplatin (0.25 mg/kg) (for 21 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
29.3 |
% |
|
23.3 |
in vivo caliper method |
0.0 |
0 |
Experiment 2 |
109487 |
3146 |
LOU/M |
maximum tumor size decrease to pretreatment tumor size ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (1 mg/kg) (for 21 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
95.8 |
% |
|
9.4 |
in vivo caliper method |
0.0 |
0 |
Experiment 2 |
109492 |
3146 |
LOU/M |
maximum tumor size decrease to pretreatment tumor size ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then cisplatin (1 mg/kg) (for 21 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
89.8 |
% |
|
14.0 |
in vivo caliper method |
0.0 |
0 |
Experiment 2 |
109489 |
3146 |
|